TipRanks
Advertisement
Advertisement

DE:UR8 Stock Latest News

UroGen Pharma falls -12.8%
The FlyUroGen Pharma falls -12.8%
2d ago
URGN
UroGen Pharma management to meet with Piper Sandler
PremiumThe Fly
UroGen Pharma management to meet with Piper Sandler
19d ago
URGN
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
PremiumCompany Announcements
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
2M ago
URGN
UroGen Pharma Expands Oncology Pipeline With SRGel Partnership
PremiumCompany Announcements
UroGen Pharma Expands Oncology Pipeline With SRGel Partnership
2M ago
8K
URGN
UroGen Pharma and IntraGel sign investment agreements in oncology therapies
PremiumThe Fly
UroGen Pharma and IntraGel sign investment agreements in oncology therapies
2M ago
URGN
UroGen Buy Rating Reaffirmed as UGN-103 Extends Bladder Cancer Franchise, $75 Price Target Maintained
PremiumRatingsUroGen Buy Rating Reaffirmed as UGN-103 Extends Bladder Cancer Franchise, $75 Price Target Maintained
2M ago
URGN
UroGen Pharma submits UGN-103 NDA to FDA
Premium
The Fly
UroGen Pharma submits UGN-103 NDA to FDA
2M ago
URGN
UroGen Pharma price target raised to $60 from $50 at Oppenheimer
Premium
The Fly
UroGen Pharma price target raised to $60 from $50 at Oppenheimer
2M ago
URGN
UroGen Pharma price target raised to $58 from $42 at Guggenheim
PremiumThe Fly
UroGen Pharma price target raised to $58 from $42 at Guggenheim
2M ago
URGN
UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright
PremiumThe Fly
UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright
2M ago
URGN
UroGen Pharma price target raised to $60 from $50 at TD Cowen
PremiumThe Fly
UroGen Pharma price target raised to $60 from $50 at TD Cowen
2M ago
URGN
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
PremiumRatings
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
3M ago
URGN
UroGen Pharma price target raised to $42 from $32 at Guggenheim
PremiumThe FlyUroGen Pharma price target raised to $42 from $32 at Guggenheim
3M ago
URGN
UroGen Pharma price target raised to $50 from $40 at Oppenheimer
Premium
The Fly
UroGen Pharma price target raised to $50 from $40 at Oppenheimer
3M ago
URGN
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
Premium
The Fly
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
3M ago
URGN
UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103
PremiumThe Fly
UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103
3M ago
URGN
UroGen Pharma announces FDA clearance for UGN-501 IND application
PremiumThe Fly
UroGen Pharma announces FDA clearance for UGN-501 IND application
3M ago
URGN
UroGen Shareholders Approve Governance, Compensation and Auditor Changes
PremiumCompany Announcements
UroGen Shareholders Approve Governance, Compensation and Auditor Changes
4M ago
8K
URGN
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
PremiumTipRanks Newswire
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
4M ago
ALMS
NVCT
Bancroft Reiterates Buy on Zusduri Upside and Pipeline Strength, Maintains $35 Price Target
PremiumRatingsBancroft Reiterates Buy on Zusduri Upside and Pipeline Strength, Maintains $35 Price Target
4M ago
URGN
UroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
Premium
Ratings
UroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
4M ago
URGN
UroGen, Teva Settle Jelmyto Patent Dispute, License Generic
Premium
Company Announcements
UroGen, Teva Settle Jelmyto Patent Dispute, License Generic
4M ago
8K
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >